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IN THEIR OWN WORDS: AN EXAMINATION OF THE EXPERIENCE OF
SEXUALITY IN INDIVIDUALS WHO HAVE UNDERGONE HEMATOPOIETIC
STEM CELL TRANSPLANTATION
Booker, R.1, Bouchal, Raffin S.2 1Tom Baker Cancer Centre, Calgary, AB,
Canada; 2University of Calgary, Calgary, AB, Canada
Objective: The primary objective of this study was to identify pa-
tients’ experience of sexuality following autologous or allogeneic he-
matopoietic stem cell transplantation (HSCT).
Methods: This study utilized a concurrent, mixed qualitative-
quantitative design. Participants completed the Functional Assess-
ment of Chronic Illness Therapy-BMT (FACT-BMT) as well as
underwent semi-structured interviews.
Results: Eleven individuals participated in the study. The mean age
at time of transplant was 43 years (range: 17-62) andmean number of
months from transplant to time of study participation was 29 (range:
2-86). Participants scored relatively high on the FACT-BMT (mean
106 [range: 56-134] out of a possible 148), where higher scores indi-
cate better quality of life. Despite the high FACT-BMT scores, the
majority of participants indicated some level of dissatisfaction with
his/her sex life. Regarding sexual function, the most common
changes experienced by the participants were: decreased libido
(67% of female participants; 63% of male participants), difficulties
with erectile function (88% of male participants), dyspareunia
(67%of female participants), vaginal dryness (100%of female partic-
ipants) and not feeling desirable (33% of female participants; 38% of
male participants). Analysis of the qualitative data obtained from the
interviews revealed several themes pertaining to sexuality andHSCT
including: changes in sexual function, the impact of the disease/treat-
ment on the participant’s relationship, the experience of discussing
sexuality with health care providers, and recommendations for po-
tential strategies that may make it easier for patients to discuss sexu-
ality with health care providers. Interview responses provided
context for the participants’ FACT-BMT scores and perspectives
on each individual’s experience with sexuality throughout the illness
and treatment trajectory.
Conclusion: In this study, 100% of participants experienced
changes in sexuality following HSCT. While many participants en-
countered changes in sexual function, the interview component of
this study revealed that sexuality, as a broader concept, went beyond
the physical realm. The study findings have led to the development
of a proposal to involve more participants as well as to include the
participants’ partners or spouses, if available.216
IMPLEMENTATION OF A POPULATION CARE MODEL UTILIZING THE
ELECTRONIC MEDICAL RECORD TO SCREEN ANDMANAGE LATE EFFECTS
OF HEMATOPOIETIC STEM CELL TRANSPLANT IS AN EFFECTIVE WAY TO
ENSURE GOOD INTERMEDIATE HEALTH OUTCOMES AND COST EFFI-
CIENT CLINICAL PROCESSES
Cheng, J.C., Hurst, M.M., Abasolo, R., Bell, E. Southern California Per-
manente Medical Group, Los Angeles, CA
Background: Despite best efforts to reduce the toxicity of condi-
tioning regimens, the development of hematopoietic stem cell trans-
plant(HSCT) related late effects remains inevitable. Recent studies
report up to 90% incidence of at least one chronic condition with
close to 25% being severe. Consistent screening efforts are key to
the early diagnosis and appropriate management of these chronic
conditions. We share our experience using an electronic medical re-
cord (EMR) system to track pediatricHSCTsurvivors in a healthcare
system that spans 12 medical centers over a large geographic area.
Hypothesis: Utilizing a population care approach to screen and
manage late effects of HSCT ensures good intermediate health out-
comes (eg handling of test results) and efficient clinical processes (eg
test frequency).
Methods: The EMR charts of 86 pediatric (0-18yrs) HSCT survi-
vors over the last 4 years were reviewed for compliance with Amer-
ican Society for Blood and Marrow Transplantation and
Childrens’ Oncology Group survivorship guidelines.
Results:Themajority of patients surveyed had timely screening and
appropriate management of visual, endocrine, cardiac, and pulmo-nary HSCT late effects concordant with published guidelines. Con-
cordance was higher within the last two years once a centralized,
designated team was formed comprised of a lead physician and nurse
case managers who were fluent in the EMR.
Conclusions: An EMR based, population care approach is a good
model for small to medium sized HSCT program to consistently
track and manage pediatric HSCT survivors. It may be especially
suited for healthcare systems that cover small numbers dispersed
over large geographic areas where centralized case management
can promote concordance with published survivorship guidelines.217
CONTRIBUTION OF GRAFT-VERSUS-HOST DISEASE TO ANDROGEN DEFI-
CIENCY INWOMEN AFTER ALLOGENEIC STEM CELL TRANSPLANTATION?
Bj€ork, Y.1, Smith-Knutsson, E.1, Ankarberg-Lindgren, C.1,
Bergmark, K.1, Wahlstr€om, E.1, Broman, A.-K.1, Anderson, H.2,
Andersson, P.-O.1, Brune, M.1 1University of Gothenburg, G€oteborg,
Sweden; 2University of Lund, Lund, Sweden
Background: After allo-HCT, ovarian failure and chronic GvHD
contribute to sexual dysfunction and reduced quality of life (QoL)
in women. We hypothesized that androgen hormone production,
both in ovaries and adrenal cortex, also might be impaired after al-
lografting. We report systemic levels of androgens in adult women
after allo-HCT compared to controls.
Patients: Twenty-four women in complete remission, 54 (3-149)
months after allo-HCT for hematological malignancies. Condition-
ing therapy was myeloablative or reduced in 11 and 13 pts, respec-
tively. Glucocorticoid treatment was ongoing in 11 pts, 10 of
whom because of chronic GvHD (cGvHD). Nine pts were on sys-
temic hormone replacement therapy (HRT). Controls were 26
healthy age matched women, 3 on HRT. The HCT group and con-
trols were similar with respect to age (mean 49 vs 50 yrs, NS), weight
(70 vs 67 kg, NS), S-albumin (mean 40 vs 41 g/L, NS), and in S-
SHBG (mean 72 vs 78 nM, NS).
Methods: Total serum testosterone was determined using a modi-
fied RIA with a sensitivity of 0.03 nM, and the biologically active
free testosterone was calculated using S-albumin and serum S-
HBG. Wilcoxon’s rank-sum test was used for comparisons.
Results: Compared to findings in the control group, free testoster-
one and dehydroepiandrosterone sulfate (DHEAS) was significantly
lower in HCT pts (5.1 vs 7.9 pM, p5 0.0008) and 1.3 vs 2.5 uM (p5
0.0009), respectively. In HCT patients with cGvHD, median free
testosterone level was 2.1 compared to 4.1 pM in patients without
cGvHD, p 5 0.046). The corresponding levels for DHEAS were
0.25 and 1.45 uM (p5 0.0009). There was a tendency to lower estra-
diol levels in HCT pts (mean 61 vs 206 pM, p5 0.09). S-LH and S-
FSHwere significantly higher inHCTpts (39 vs 19U/L p5 0.0001,
and 59 vs 33 U/L, p5 0.005, respectively). Within the HCT group,
there were no significant differences in free testosterone and
DHEAS levels with respect to weight, previous acute GvHD, condi-
tioning intensity or ongoing HRT.
Conclusions:Our findings of low testosterone and DHEAS suggest
that not only ovarian dysfunction, but also a reduced adrenal steroid
production contributes to low androgen levels. The androgen defi-
ciency observed, possibly related to cGvHD and corticoid steroid
treatment, could be an additional cause of impaired vitality and sex-
ual dysfunction reported after allo-HCT.218
FERTILITY PRESERVATION IN PEDIATRIC PATIENTS UNDERGOING STEM
CELL TRANSPLANTATION: SPERM BANKING BEFORE OR AFTER
CHEMOTHERAPY
Sheth, K.R.1, Sharma, V.1, Lockart, B.A.2, Brannigan, R.E.1,
Gosiengfiao, Y.C.2 1NorthwesternUniversity Feinberg School of Medicine,
Chicago, IL; 2Northwestern University Children’s Memorial Hospital,
Chicago, IL
Purpose: As survival rates among stem cell transplant (SCT) pa-
tients continue to improve, the long-term consequences of
S284 Poster Session Iaggressive chemotherapy and radiotherapy on future fertility are
being increasingly realized in males. To counteract such deleteri-
ous effects, we initiated a formal fertility preservation program in
2007 to increase access to sperm cryopreservation (SCP) services
at our institution. Here we analyze our program’s utility and pa-
tient data to provide insight into fertility preservation prior to
SCT.
Methods: An IRB-approved chart review was conducted on all male
pediatric patients older than 13 years who underwent SCT between
January 2008 and June 2010 at our institution. Patients given a fertil-
ity preservation consult were identified, and the semen parameters of
those subsequently banking sperm were obtained.
Results:During the study interval, 22 male pediatric patients met
our study criteria, of which there were 19 allo-transplants and 3
auto-transplants. 8/22 (36%) patients were given fertility preserva-
tion consults and 6/22 (27%) proceeded to SCP, a consult success
rate of 75% (Table 1). 6/13 (38%) patients with planned radio-
therapy were consulted, compared to 2/9 (22%) patients with no
planned radiotherapy. Of the 6 patients banking sperm, 3 banked
prior to chemotherapy while 3 banked after. The average semen
parameters of patients banking before chemo vs after chemo-
therapy were as follows: Volume 2.50 vs 1.50 ml; Concentration
30.7 vs 30.6 million/ml; Motility 36.7% vs 21.3%; Normal
Morphology 9.7% vs 3.5%. Thus, while patients who banked
after chemotherapy had sub-fertile semen parameters, their bulk
semen parameters were still adequate for cryopreservation. All
bulk semen parameters tended to improve as age at banking
increased.
Conclusions:The high fertility preservation consult success rate in-
dicates a large desire to preserve fertility in patients planning SCT.
While bulk semen parameters were adequate for cryopreservation
in patients after treatment, DNA damage resulting from chemother-
apy was not assessed. Although cryopreservation of some sperm is
preferred over none, ample literature supports the notion that che-
motherapy has a deleterious effect on fertilization and embryo devel-
opment outcomes. Thus, every effort should be made to
cryopreserve sperm prior to chemotherapy and radiation. Finally,
further initiatives are required to extend the opportunity of fertility
preservation to all SCT patients.
Table 1. Demographic Comparison of All SCT Patients vs.
Consulted Patients
All Patients (N 5 22) Consulted Patients (N 5 8)Year
2008 10 4
2009 9 3




African American 4 1
Hispanic 5 2
Other 1 0219
REPEAT READMISSIONS AFTER ALLOGENEIC HEMATOPOIETIC
PROGENITOR CELL TRANSPLANTATION (HPCT)
Hamilton, B.K.1, Serafino, S.1, Kalaycio, M.1, Andresen, S.1,
Pohlman, B.1, Dean, R.1, Hill, B.T.1, Hanna, R.2, Duong, H.1,
Sweetenham, J.W.1, Copelan, E.A.1, Bolwell, B.J.1, Sobecks, R.1
1Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; 2Cleveland
Clinic Taussig Cancer Institute, Cleveland, OH
Hospital readmissions increase healthcare cost and are a target
of ways to improve cost and quality of medical care. Patients (pts)
who undergo allogeneic hematopoietic progenitor cell transplant
require a high level of care and are often readmitted. Thirty-day
hospital readmissions following allogeneic HPCT, however, are
associated with poor survival. In this retrospective review, weevaluated our 30-day readmissions for allogeneic HPCT occur-
ring in 2010 at our institution. The analysis included pts who
were not only transplanted in 2010 but also those who had
been previously transplanted (ranging from 1994-2010), and later
hospitalized again in 2010 and subsequently readmitted within
30 days.
There were 83 total readmissions for allogeneic transplant pts
within 30 days of a prior hospitalization in 2010. Only 47 pts,
however, accounted for these readmissions and 19 (23%) pts
were admitted multiple times (range 2-5 times), accounting for
55 (66%) of the readmissions. Initial diagnoses for pts admitted
more than once included: 7 refractory NHL, 4 AML, 3 ALL, 2
MDS, 2 AA and 1 CML. Donor type included 4 UCB, 5 MUD
and 10 MSD. Fifty-two percent (n 5 10) had a CIBMTR trans-
plant co-morbidity index score of .2. Fifty-three (64%) of the
30d readmissions after allogeneic HPCT were due to infection
or unexplained fever, followed by 9 (11%) for symptoms related
to GVHD, 7 (8%) due to cardiac complications (CHF, arrhyth-
mias), and 14 (17%) others related to symptom management
(pain, nausea/vomiting, diarrhea not related to infection or
GVHD). Looking specifically at reasons for subsequent repeated
readmissions demonstrated a similar distribution with the majority
of re-hospitalizations being for infection or unexplained fever, fol-
lowed by symptom management, cardiac complications, and
GVHD. There were 13 deaths, all related to infection or compli-
cations from GVHD. Median time to death after readmission was
27 days (range, 0 to 96).
Readmissions for allogeneic HPCT are associated with worse
survival. In this retrospective review we have found that the ma-
jority of readmissions were from pts admitted multiple times.
About half of these pts were identified as having higher co-
morbidity index scores. Further prospective studies of readmission
trends in allogeneic transplant and identification of high risk pts
who may be susceptible to multiple readmissions may help de-
crease readmission rates, transplant outcomes, and improve overall
quality of care.220
VENOUS THROMBOEMBOLISM IN ALLOGENEIC HEMATOPOEITIC STEM
CELL TRANSPLANTATION – THE INCIDENCE, CHARACTERISTICS AND
MANAGEMENT – A SINGLE INSTITUTION EXPERIENCE
Wudhikarn, K.1, Gingrich, R.D.1, Leopold, C.2, Silverman, M.1 1Uni-
versity of Iowa, Iowa City, IA; 2Holden Comprehensive Cancer Center,
Iowa City, IA
Background: The association between venous thromboembolism
(VTE) and hematologic malignancy is well established. However,
VTE after allogeneic hematopoietic cell transplantation (HCT) is
not well characterized. The management is not standardized and
varies between hematologists.
Methods: A total of 260 patients underwent allogeneic HCT at
the University of Iowa between 2004 and 2009. Patient’s data
were retrospectively abstracted from the electronic medical record
and bone marrow transplant database. We report the incidence,
characteristics, management and outcome of VTE following
allotransplant.
Results: Of 260 patients who underwent allogeneic HCT, 35
(13.5%) developed VTE events. The median time from transplant
to VTE diagnosis was 121 days (-3 to 1853 d). Twenty-two pa-
tients (63%) developed VTE during the first six months post allo-
transplant. Sixteen patients (47%) had central venous catheter
related VTE. At VTE diagnosis, six patients (17%) had active he-
matologic malignancy and 18 patients (51%) had active GVHD ($
grade III). The median platelet count at VTE diagnosis was 65
(5-676) x 106/mm3. Twenty-five patients (71%) received systemic
anticoagulation (17 heparin products VS 8 heparin followed by
warfarin). Eight of 25 patients (32%) who had anticoagulation
treatment received therapeutic dose of anticoagulant whereas 17
patients had prophylactic dose. Among 10 patients who did not
receive systemic anticoagulation treatment either due to clinical ac-
tive bleeding or severe thrombocytopenia, two underwent inferior
vena cava filter placement. Eight patients (32%) had hemorrhagic
complications during anticoagulation. The median anticoagulation
